Singapore markets open in 1 hour 1 minute

Bio-Rad Laboratories, Inc. (BIO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
280.13+0.40 (+0.14%)
At close: 04:00PM EDT
280.13 0.00 (0.00%)
After hours: 05:12PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close279.73
Open281.73
Bid280.53 x 1200
Ask281.20 x 3000
Day's range277.71 - 283.42
52-week range261.59 - 473.50
Volume176,568
Avg. volume208,706
Market cap7.99B
Beta (5Y monthly)0.88
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

    HERCULES, Calif., April 18, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.

  • GlobeNewswire

    Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

    - Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the c

  • Business Wire

    Bio-Rad’s Chief Operating Officer Andrew Last to Retire

    HERCULES, Calif., April 10, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of Bio-Rad’s executive leadership team to ensure a smooth transition while the company conducts a search for his successor.